GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » 3-Year EPS without NRI Growth Rate

CureVac NV (WBO:CVAC) 3-Year EPS without NRI Growth Rate : -30.60% (As of Sep. 2023)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV 3-Year EPS without NRI Growth Rate?

CureVac NV's EPS without NRI for the three months ended in Sep. 2023 was €-0.22.

During the past 3 years, the average EPS without NRI Growth Rate was -30.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 5 years, the highest 3-Year average EPS without NRI Growth Rate of CureVac NV was -30.60% per year. The lowest was -75.60% per year. And the median was -53.10% per year.


Competitive Comparison of CureVac NV's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, CureVac NV's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CureVac NV's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where CureVac NV's 3-Year EPS without NRI Growth Rate falls into.



CureVac NV 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


CureVac NV  (WBO:CVAC) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


CureVac NV 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of CureVac NV's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV (WBO:CVAC) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » 3-Year EPS without NRI Growth Rate
Traded in Other Exchanges
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.